Navigation Links
Multikine in Medical News

CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results

...oduct in the country. CEL-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. Launch of cold 4 d...rehensive immunotherapy that targets newly diagnosed head and neck cancer. multikine is cleared by the FDA and the Canadian regulators for a global Phase III cl...

CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa

...-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. ...or registering the product in the Territory. Once multikine has been approved, CEL-SCI will be responsible for...reement is consistent with our strategy to license multikine in the emerging markets to share the expenses of b...

CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference

...gave clearance for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

CEL-SCI Corporation Reports Second Quarter 2008 Financial Results

..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial

...cess, eliminating a key risk of the pivotal trial. multikine represents a completely novel medicine with blockb...reak the annual billion-dollar sales barrier'. Our multikine was one of the 10 medicines named." The article ...of the highlights include: -- FDA clearance of multikine for Phase III clinical trial in head and neck ...

CEL-SCI Corporation Releases Letter to Shareholders

... Company highlights of 2007: -- FDA clearance of multikine for Phase III clinical trial in head and neck cancer -- Raised U.S. $15 million -- multikine granted Orphan drug designation in U.S. -- Started build-out of manufacturing facility for multikine to support upcoming Phase III study and commer...

CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan

...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin... a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI

... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head an...

New Help for Head and Neck Cancer

...oost the immune system. Patients received the multikine injections for 10 days. Two patients had a complet...e seen with the therapy. The authors conclude multikine injections may be valuable in the treatment of hea...fine the best dosage and mode of administration of multikine in patients with head and neck cancer.” ...
Multikine in Medical Technology

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...

CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug

Biomedical Real Estate Group Backs Construction of Facility VIENNA, Va., Aug. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM ) announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

Partner to Make Direct Investment in CEL-SCI VIENNA, Va., Nov. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has expanded its exclusive licensing agreement for Multikine(R) with Orient Europharma Co., Ltd. ("Orient Europharma"), a leading pharmaceutica...

CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer pat...

CEL-SCI Corporation Releases Letter to Shareholders

...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...n the go-ahead for a Phase III clinical trial with multikine and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...

CEL-SCI Corporation Releases Letter to Shareholders

... Teva will participate in and pay for part of the multikine Phase III trial. We extended our multikine licensing agreement with Orient EuroPharma of Ta... our Phase III trial. multikine was named one of 10 future blockbuster drugs by M...

CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

... 8, 2008. This dedicated facility will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ... our product development." CEL-SCI is developing multikine for approval as a first line indication in head an...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head ...

CEL-SCI Corporation Reports First Quarter Financial Results

...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...is currently building a manufacturing facility for multikine close to Baltimore, MD. Upon completion of the fac...
Multikine in Biological News

CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products

...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
Multikine in Biological Technology

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...

CEL-SCI Corporation Releases Letter to Shareholders

...facturing. This facility was built to manufacture multikine for the Phase III trial and sale thereafter. Due ...ng anywhere else. This means that we can fill our multikine into vials in a completely sterile manner not only... pharmaceutical/biotechnology drug industry. multikine cancer therapy: We believe that the most cri...

CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering

...eration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug multikine for the planned Phase III clinical trial." The securities described above are being offered by CEL-SCI Corporation pursuant to a registration sta...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

...ntigen specificity with immune response modulation. CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this...

CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products

...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...

CEL-SCI Corporation Announces 2008 Financial Results

... fiscal 2008 in preparing for our pivotal trial of multikine for head and neck cancer. Expenditures for 2009 ar...sh expenditures. In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to...

CEL-SCI Corporation Releases Letter to Shareholders

...people had expected and clearly make our non-toxic multikine cancer product even more important to develop. Se... Organization (BIO) which would help CEL-SCI bring multikine to market faster. Last, what percentage of people...er I also want to review the general status of our multikine cancer drug: 1. In the last few months we...

Updated Pictures of CEL-SCI Manufacturing Facility Available Online

...ng and FDA cleared Phase III clinical trial, as well as commercial sale, of multikine as a first line indication in treatment naive head and neck cancer patients...h other potential partners are ongoing. In Phase II clinical trials multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% ...

CEL-SCI Takes Delivery of New Manufacturing Facility

...y, located in the Baltimore area, will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ...n line for manufacturing." CEL-SCI is developing multikine for approval as a first line indication in head an...

CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results

...g facility and starting the Phase III study of our multikine cancer drug. Some additional funds were spent on o..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...
Other Tags
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
(Date:4/15/2014)... associate professor of mechanical engineering at Worcester ... the university,s Integrative Materials Design Center (iMdc), ... from leading engineering societies. , At its ... global association of more than 138,000 engineers ... aerospace, and commercial vehicle industries, presented Lados ...
(Date:4/15/2014)... who study the deadliest infectious diseases recognized the contributions ... at the University of Texas Medical Branch, with a ... on Filoviruses. The filoviruses include Ebola and Marburg viruses ... people infected. The current outbreak of Ebola virus raging ... so far. , "This award represents the culmination ...
(Date:4/15/2014)... Md. (April 15, 2014) The American Association ... award winners. All awards will be presented during ... Diego Marriott Hotel on Tuesday, April 29th at 7:30 ... (EB). , The 2014 award winners are: ... Jeffrey Laitman, PhD, of the Icahn School of Medicine ...
Breaking Biology News(10 mins):WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3American Association of Anatomists 2014 award winners 2
Other Contents